Free preview. Sign up free to see the team, full portfolio, ownership chain, and shareholding history.
Earlybird Health Ii Fund Gmbh & Co. Kg investment portfolio
Earlybird Health Ii Fund Gmbh & Co. Kg has made numerous investments in companies such as Prothea Technologies, Grey Wolf Therapeutics, and Portal Biotech within the Healthcare & Life Sciences sector.
vc
Portfolio
4
Team
0
Portfolio (4)
| Company | Sector | City | Source | Last confirmed on |
|---|---|---|---|---|
| Axon Vascular Europe Limited Axon Vascular Europe develops a minimally invasive, implant‑free medical device that ablates a greater splanchnic nerve to treat heart failure, targeting patients requiring advanced cardiac therapy. | Healthcare & Life Sciences | Altrincham | Confirmed | — |
| Grey Wolf Therapeutics Limited Grey Wolf Therapeutics Limited is a clinical‑stage biotechnology company that develops antigen‑modulation therapies—small‑molecule drugs that alter the first step of T‑cell signaling—to treat cancer and autoimmune diseases. Its work focuses on research and experimental development of novel immuno‑oncology therapeutics. | Healthcare & Life Sciences | Abingdon | Confirmed | 2025-10-27 |
Backs Similar Companies
Investors who tend to invest in the same sort of companies.
5 more similar investors hiddenSign up to unlock →
Shareholding changes (5)
Earlybird Health Ii Fund Gmbh & Co. Kg's positions across portfolio companies2026
- SERIES A SHARES OF 0.001 314,285 → 571,427
- SERIES A1 PREFERRED 0 → 20,749
Articles (1)
- NATO Innovation Fund takes 12.6% stake in Portal Biotech18 Jun 2026Portal Biotech